A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of TMC435 compared with
placebo in combination with peginterferon alfa-2a (pegIFN alfa-2a) and ribavirin in
treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) infection in Japan.